Type A lactic acidosis resulted from hypoxic mitochondrial dysfunction is an independent predictor of mortality for critically ill patients. However

current therapeutic agents are still in shortage and can even be harmful. This paper reviewed data regarding lactic acidosis treatment and recommended that pyruvate might be a potential alkalizer to correct type A lactic acidosis in future clinical practice. Pyruvate is a key energy metabolic substrate and a pyruvate dehydrogenase（PDH） activator with several unique beneficial biological properties

including anti-oxidant and antiinflammatory effects and the ability to activate the hypoxia-inducible factor-1（HIF-1α）-erythropoietin（EPO） signal pathway. Pyruvate preserves glucose metabolism and cellular energetics better than bicarbonate

lactate

acetate and malate in the efficient correction of hypoxic lactic acidosis and shows few side effects. Therefore

application of pyruvate may be promising and safe as a novel therapeutic strategy in hypoxic lactic acidosis correction accompanied with multi-organ protection in critical care patients.